Medigus Ltd (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and direct visualisation technology, announced its financial results for the third quarter of 2017 on Friday.

The company reported revenues for the three months ended 30 September 2017 at USD117,000, down 14% against the year-ago period. Research and development expenses for the three months ended 30 September 2017, were USD654,000, a decrease of 8%, compared to the three months ended 30 September 2016.

The firm posted operating loss for the three months ended 30 September 2017 at USD1,255,000, compared with USD1,947,000 in the same period in 2016.